Regeneron Announces Upcoming September 2018 Investor Conference Presentation

     

TARRYTOWN, N.Y., Aug. 24, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its management presentation at the Morgan Stanley 16th Annual Global Healthcare Conference at 9:55 a.m. Eastern Time on Wednesday, September 12, 2018.

The session may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron.com/events.cfm. A replay of the webcast will be archived on the Company's website and will be available for 30 days.

About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to six FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

 

    Contact Information:

    Investor Relations               Corporate Communications

    Manisha Narasimhan, Ph.D.        Hala Mirza

    914.847.5126                     914.847.3422

    manisha.narasimhan@regeneron.com hala.mirza@regeneron.com

 

View original content:http://www.prnewswire.com/news-releases/regeneron-announces-upcoming-investor-conference-presentation-300701709.html

SOURCE Regeneron Pharmaceuticals, Inc.

   
Company Codes: NASDAQ-NMS:REGN  

Back to news